Page 69 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் Today - Breaking & Trending Today

Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting


Share this article
Share this article
INDIANAPOLIS, April 11, 2021 /PRNewswire/  Eli Lilly and Company (NYSE: LLY) today announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo
® (selpercatinib) demonstrated encouraging antitumor activity and safety across
RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal (GI) malignancies. The data were presented at the 2021 American Association for Cancer Research (AACR) Annual Meeting, held virtually April 10-15, 2021.
We are excited to broaden the body of evidence for Retevmo in
RET fusion-positive cancers beyond lung and thyroid tumors, said David Hyman, M.D., chief medical officer, oncology at Lilly. These encouraging outcomes, including in difficult-to-treat GI malignancies, support a growing body of evidence that ....

United States , Vivek Subbiah , Kevin Hern , David Hyman , Eli Lilly , Tracy Henrikson , University Of Texas Md Anderson Cancer Center , Cancer Medicine Division , Drug Administration , Lilly United States , Exchange Commission , American Association For Cancer Research , Lilly Research Laboratories , Investigational Cancer Therapeutics Department , Clinical Center , Cancer Research , Annual Meeting , Targeted Therapy , Accelerated Approval , European Commission , Response Evaluation Criteria , Solid Tumors , Glomerular Filtration Rate , Renal Disease , Prescribing Information , Loxo Oncology ,

MD Anderson researchers highlight advances in clinical studies at AACR Annual Meeting 2021